Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02174172 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 158
- Enrollment target
NCT02174172 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 158 participants.
The verdict
NCT02174172, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 158 participants
- Enrollment target
Study Summary
This global, multicenter, open-label study will evaluate the safety and tolerability of atezolizumab in combination with other immune-modulating therapies in the treatment of selected advanced or metastatic malignancies. The atezolizumab plus ipilimumab arm (Arm A) will focus primarily on participants with advanced or metastatic non-small cell lung cancer (NSCLC). The atezolizumab plus interferon alfa-2b arm (Arm B), plus pegylated interferon alfa-2a (PEG-interferon alfa-2a, Arm C), and atezolizumab plus PEG-interferon Alfa-2a plus bevacizumab (Arm D) will enroll participants with advanced or metastatic renal cell carcinoma (RCC), metastatic NSCLC and melanoma. The atezolizumab plus obinutuzumab) (Arm E) will enroll participants with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Atezolizumab will be administered as intravenous (IV) infusion every 3 weeks (q3w).
Interventions
- DRUG Obinutuzumab
- DRUG Bevacizumab
- DRUG Atezolizumab
- DRUG Ipilimumab
- DRUG Interferon alfa-2b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2014-08-18 |
| Est. Completion | 2019-11-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02174172
The ClinicalTrials.gov registry entry for NCT02174172 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Obinutuzumab is the first listed.
NCT02174172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02174172 about?
NCT02174172 is a clinical study titled "A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors". This global, multicenter, open-label study will evaluate the safety and tolerability of atezolizumab in combination with other immune-modulating therapies in the treatment of selected advanced or metastatic malignancies. The atezolizumab plus ipilimumab arm (Arm A) will focus primarily on participan...
What is the current status of trial NCT02174172?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 158 participants. The study started on 2014-08-18. Estimated completion is 2019-11-25.
What interventions are being tested in trial NCT02174172?
The interventions under investigation include: Obinutuzumab (DRUG), Bevacizumab (DRUG), Atezolizumab (DRUG), Ipilimumab (DRUG), Interferon alfa-2b (DRUG).
Who is sponsoring clinical trial NCT02174172?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.